The article discusses efficacy of enfortumab vedotin to treat advanced urothelial cancer. Topics discussed include approval of enfortumab vedotin for the treatment of patients with advanced or metastatic urothelial cancer who have received platinum-based chemotherapy and PD-1/PD-L1 therapy; challenges in treatment after platinum-based chemotherapy and immune checkpoint inhibitors; and response rates to enfortumab vedotin.